Suppr超能文献

2019 冠状病毒病患者的器官功能支持:同济经验。

Organ function support in patients with coronavirus disease 2019: Tongji experience.

机构信息

Department of Respiratory and Critical Care Medicine, Department of Internal Medicine, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, 430030, China.

Department of Nephrology, Department of Internal Medicine, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, 430030, China.

出版信息

Front Med. 2020 Apr;14(2):232-248. doi: 10.1007/s11684-020-0774-9. Epub 2020 May 14.

Abstract

Coronavirus disease 2019 (COVID-19) is a highly contagious disease and a serious threat to human health. COVID-19 can cause multiple organ dysfunction, such as respiratory and circulatory failure, liver and kidney injury, disseminated intravascular coagulation, and thromboembolism, and even death. The World Health Organization reports that the mortality rate of severe-type COVID-19 is over 50%. Currently, the number of severe cases worldwide has increased rapidly, but the experience in the treatment of infected patients is still limited. Given the lack of specific antiviral drugs, multi-organ function support treatment is important for patients with COVID-19. To improve the cure rate and reduce the mortality of patients with severe- and critical-type COVID-19, this paper summarizes the experience of organ function support in patients with severe- and critical-type COVID-19 in Optical Valley Branch of Tongji Hospital, Wuhan, China. This paper systematically summarizes the procedures of functional support therapies for multiple organs and systems, including respiratory, circulatory, renal, hepatic, and hematological systems, among patients with severe- and critical-type COVID-19. This paper provides a clinical reference and a new strategy for the optimal treatment of COVID-19 worldwide.

摘要

新型冠状病毒肺炎(COVID-19)是一种高传染性疾病,严重威胁人类健康。COVID-19 可引起多器官功能障碍,如呼吸和循环衰竭、肝肾功能损伤、弥散性血管内凝血、血栓栓塞等,甚至死亡。世界卫生组织报告称,重型 COVID-19 的死亡率超过 50%。目前,全球重型病例数量迅速增加,但感染患者的治疗经验仍有限。鉴于缺乏特效抗病毒药物,多器官功能支持治疗对 COVID-19 患者非常重要。为提高重型和危重型 COVID-19 患者的治愈率,降低死亡率,本文总结了中国武汉同济医院光谷院区重型和危重型 COVID-19 患者的器官功能支持治疗经验。本文系统总结了重型和危重型 COVID-19 患者呼吸、循环、肾、肝、血液等多器官和系统功能支持治疗的流程,为全球 COVID-19 的最佳治疗提供了临床参考和新策略。

相似文献

5
Pathophysiology and treatment strategies for COVID-19.COVID-19 的病理生理学和治疗策略。
J Transl Med. 2020 Sep 15;18(1):353. doi: 10.1186/s12967-020-02520-8.
6
COVID-19 challenge for modern medicine.现代医学面临的 COVID-19 挑战。
Cardiol J. 2020;27(2):175-183. doi: 10.5603/CJ.a2020.0055. Epub 2020 Apr 14.
7
Treatment considerations for coronavirus (COVID-19).冠状病毒(COVID-19)的治疗考量
Hosp Pract (1995). 2020 Aug;48(3):119-120. doi: 10.1080/21548331.2020.1754618. Epub 2020 Apr 13.

引用本文的文献

1
Thyroid Dysfunction among the Patients with Critical COVID-19.重症新型冠状病毒肺炎患者的甲状腺功能障碍
Infect Dis Clin Microbiol. 2022 Dec 21;4(4):229-235. doi: 10.36519/idcm.2022.175. eCollection 2022 Dec.
4
Liver injury in COVID-19: Known and unknown.新型冠状病毒肺炎中的肝损伤:已知与未知
World J Clin Cases. 2021 Jul 6;9(19):4980-4989. doi: 10.12998/wjcc.v9.i19.4980.
7
Thyroid Function Abnormalities in COVID-19 Patients.新型冠状病毒肺炎患者甲状腺功能异常。
Front Endocrinol (Lausanne). 2021 Feb 19;11:623792. doi: 10.3389/fendo.2020.623792. eCollection 2020.
10
COVID-19 and Thyroid: Progress and Prospects.COVID-19 与甲状腺:进展与展望。
Int J Environ Res Public Health. 2020 Sep 11;17(18):6630. doi: 10.3390/ijerph17186630.

本文引用的文献

8
[Analysis of clinical features of 29 patients with 2019 novel coronavirus pneumonia].[29例2019新型冠状病毒肺炎患者临床特征分析]
Zhonghua Jie He He Hu Xi Za Zhi. 2020 Feb 6;43(0):E005. doi: 10.3760/cma.j.issn.1001-0939.2020.0005.
10
First Case of 2019 Novel Coronavirus in the United States.美国首例 2019 新型冠状病毒病例。
N Engl J Med. 2020 Mar 5;382(10):929-936. doi: 10.1056/NEJMoa2001191. Epub 2020 Jan 31.

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验